Periodontal Therapeutics Market expected to gain significant market traction during the forecast period

The global periodontal therapeutics market valued USD 644.8 million in 2020 and is estimated to reach USD 1,221.1 million by 2028, growing at a CAGR of 8.6% during the forecast period (2021-2028).

Periodontal disease, commonly known as gum disease, is a major dental health disease associated with inflammation and infection of gums surrounding the teeth. Periodontitis is a very common condition, usually caused by poor oral hygiene, and can be prevented in most cases by surgical, non-surgical or therapeutic treatment procedures Periodontal therapeutics include the use of antibiotics alone for the treatment of periodontitis and is relatively a small but lucrative method, gaining promise among patients and dentists globally The North America region witnessed the largest share by region of 34% in terms of sales revenue in 2020 owing to the large prevalence of periodontal disease in the U.S.

Market Dynamics

Drivers

• Rising prevalence of periodontal diseases
• Robust Pipeline drugs

Restraints

• Use of alternative oral hygiene products
• Clinical inefficiencies of antibiotics

Robust Pipeline drugs 

The global periodontal therapeutics market is witnessing a large number of clinical developments and product launches, thereby resulting in increased prescription and market demand. Large pharmaceutical companies and healthcare associations are focusing towards advanced therapeutics for non-surgical treatment of gum disease

The use of antibiotics, particularly systemic antibiotics as first-line therapy in periodontitis is rapidly growing with innovation of new products. These innovations are likely to cater the unmet needs of periodontal disease patients globally

Biological therapeutics is another key area of development in the periodontal therapeutics market. With increasing evidence towards role of biologics in dental health, focus is laid towards use of promotion of biologic agents for periodontal regeneration

For instance, Trafermin – a fiblast spray developed by Kaken Pharmaceutical was approved for use in treatment of periodontitis in Japan in 2016.

In 2017, Geistlich Pharma conducted Phase 2 clinical trials of PerioSept, which is a new experimental gel formulation. PerioSept is developed to be used as an adjunctive therapy for periodontitis treatment. 

In March 2021, Amyndas Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of novel complement therapeutics, announced positive top-line Phase 2 results from its randomized, placebo-controlled clinical trial evaluating AMY-101 in 39 patients with periodontal inflammation and gingivitis.

Geographical Analysis

Middle East and Africa Periodontal Therapeutics market is likely to reach USD 59.6 million in 2028, from its recorded value of USD YY million in 2020, growing with a CAGR of 7.8% during the forecast period. Countries such as Saudi Arabia, UAE, and Israel are witnessing an increased demand for periodontal therapeutics

Saudi Arabia has increasing diabetic population pool. According to the World Health Organization (WHO), Saudi Arabia has the second highest diabetes rate in the Middle East and ranks seventh globally. Around 7 million people are diabetic, and almost 3 million have pre-diabetes, according to estimates. This is expected to increase the demand for periodontal therapeutics in Saudi Arabia as diabetes increases inflammation in periodontal tissues, leading to periodontal disease

In the United Arab Emirates, oral health spending is registered to have grown relating to periodontal diseases and dental caries treatment, as per Health Authority Abu Dhabi (HAAD). Moreover, the tooth decay rate is higher among the children, whereas the periodontal disease is highly prevalent among adults. HAAD introduced an oral health initiative, under the theme ‘Healthy Mouth Health Body’ to address the oral health problems experienced by the population, which is motivating the periodontal therapeutics progression during the forecast period

Oral diseases are rapidly being recognized as a major public health concern in Africa. In 2017, it was estimated that 400 million people in the WHO African Region suffered from some sort of oral disease. Periodontal disease (gingivitis) remains widespread and severe, poor oral hygiene remains the norm, and calculus deposits are common. In 2017, the WHO African Region assessed that 12–14 percent of 35–44-year-olds and 22 percent of 60–69-year-old people had severe periodontal (gum) disease that could lead to tooth loss

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com